Noninterventional retrospective study of standard-of-care systemic treatment patterns and outcomes in US patients with advanced urothelial carcinoma
The Oncologist · 2025
DOI: 10.1093/oncolo/oyaf071 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, 2025. Verfasst von Helen H Moon und 12 weiteren Autor:innen. Beteiligte Einrichtung: Kaiser Permanente Southern California, Riverside, CA, USA. Hauptthemen laut MEDLINE: Standard of Care, Urologic Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Transitional Cell. Die Arbeit nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer, Merck.
Abstract (Originalsprache)
Background
First-line platinum-based chemotherapy (1L PBC) followed by avelumab 1L maintenance (1LM) in patients without disease progression after 1L PBC is a standard-of-care treatment in locally advanced/metastatic urothelial carcinoma (la/mUC). We examined real-world treatment patterns and outcomes in patients with la/mUC treated in the US and characterized early adoption of avelumab 1LM following US Food and Drug Administration approval in June 2020. Materials and methods This retrospective cohort study identified patients ≥ 18 years diagnosed with la/mUC between January 2015 and July 2021 using electronic health records from the Flatiron Health database. Treatment patterns and baseline characteristics were described by type of 1L treatment. Real-world progression-free survival (rwPFS) and real-world overall survival (rwOS) were determined using the Kaplan-Meier method.
Results
A total of 4387 patients were included, with 3706 (84.5%) receiving systemic treatment. The most common 1L therapy was cisplatin-based therapy (33.3%), followed by carboplatin-based (30.9%) and immuno-oncology (IO) therapies (28.0%). Patients treated with 1L cisplatin-based therapy had longer median rwPFS and rwOS from 1L initiation (8.0 and 18.3 months, respectively) vs patients treated with 1L carboplatin-based therapy (6.4 and 13.2 months), or IO therapies (6.1 and 14.2 months). Among eligible patients, early use of avelumab 1LM was 29%. Approximately half (51.7%) of treated patients received second-line (2L) treatment, 16.8% received no 2L treatment, and 31.5% remained on 1L at end of study.
Conclusion
Our findings contribute to our understanding of optimal treatment sequencing options based on individual patient characteristics in a rapidly evolving treatment landscape.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Kaiser Permanente Southern California, Riverside, CA, USA.
- Pfizer, New York, NY, USA.
- Genesis Research, LLC, Hoboken, NJ, USA.
- EMD Serono, Inc., Boston, MA, USAan affiliate of Merck KGaA.
- Merck Healthcare KGaA, Darmstadt, Germany.
ORCID-Profile: Helen H Moon
Förderung
- Pfizer
- Merck
Zitieren
APA
Moon, H. H., Kirker, M., Abraham, A., Vlahiotis, A., Bhanegaonkar, A., Ike, C., Benjumea, D., Kim, C., Sun, H., Kearney, M., Chandrasekar, S., Li, B., & Thakkar, S. (2025). Noninterventional retrospective study of standard-of-care systemic treatment patterns and outcomes in US patients with advanced urothelial carcinoma. The Oncologist. https://doi.org/10.1093/oncolo/oyaf071
Vancouver
Moon HH, Kirker M, Abraham A, Vlahiotis A, Bhanegaonkar A, Ike C, et al. Noninterventional retrospective study of standard-of-care systemic treatment patterns and outcomes in US patients with advanced urothelial carcinoma. The Oncologist. 2025. doi:10.1093/oncolo/oyaf071
BibTeX
@article{Moon2025,
author = {Moon, Helen H and Kirker, Melissa and Abraham, Anup and Vlahiotis, Anna and Bhanegaonkar, Abhijeet and Ike, Chiemeka and Benjumea, Darrin and Kim, Chai and Sun, Haiyan and Kearney, Mairead and Chandrasekar, Sanjana and Li, Benjamin and Thakkar, Sheena},
title = {Noninterventional retrospective study of standard-of-care systemic treatment patterns and outcomes in US patients with advanced urothelial carcinoma},
journal = {The Oncologist},
year = {2025},
doi = {10.1093/oncolo/oyaf071}
}
EUVIMED